Table 2.

Crude and adjusted HRs for AMD among new users of sildenafil compared with those not prescribed sildenafil

	Sildenafil use	Non-sildenafil use
Patients with erectile dysfunction	31 575	62 155
AMD, n (%)	234 (0.7)	398 (0.6)
Total person-years of follow-up	142 790.6	250 636.3
Median follow-up, years	3.6 (1.6–6.3)	3.1 (1.3–5.5)
Crude incidence rate/1000 person-years	1.64	1.59
Unadjusted HR (95% CI)	1.02 (0.87 to 1.20); p=0.770
Adjusted HR* (95% CI)	0.99 (0.84 to 1.16); p=0.884

*Adjusted for age, ethnicity, Townsend deprivation quintiles, BMI category, smoking status and comorbidities, including hypertension and type 2 diabetes status.

AMD, age-related macular degeneration; BMI, body mass index.